Search filters

List of works by Martine Piccart-Gebhart

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

scientific article

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

scientific article published on 10 December 2012

Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn

scientific article published on 27 June 2006

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial

scientific article

Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience

scientific article published on 28 January 2013

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

scientific article

Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib

scientific article published on 09 December 2009

Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature

scientific article published on 19 April 2014

Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy

scientific article

Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?

scientific article published on April 2009

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study

scientific article

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?

scientific article

Clinical application of the 70-gene profile: the MINDACT trial

scientific article

Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer

scientific article published on December 2008

Development and validation of gene expression profile signatures in early-stage breast cancer

scientific article published on January 2009

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be t

scientific article published on 28 January 2016

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

scientific article published on 13 April 2009

Dissecting the heterogeneity of triple-negative breast cancer

scientific article published on 26 March 2012

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials

scientific article

Facts and controversies in the use of trastuzumab in the adjuvant setting

scientific article published on 09 September 2008

Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients

scientific article

Genomic grade index is associated with response to chemotherapy in patients with breast cancer

scientific article published on 13 April 2009

HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?

scientific article published on June 2008

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

scientific article

How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer

scientific article

Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25.

scientific article

Jumping higher: is it still possible? The ALTTO trial challenge

scientific article published on December 2008

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

scientific article

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

scientific article published on 16 April 2015

Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial

scientific article published on 15 April 2013

Molecular targeted therapies in breast cancer: where are we now?

scientific article published on 4 May 2007

Multifactorial approach to predicting resistance to anthracyclines

scientific article published on 21 March 2011

New generation of breast cancer clinical trials implementing molecular profiling

scientific article published on June 2016

New therapies for ovarian cancer: cytotoxics and molecularly targeted agents

scientific article published on 14 March 2008

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

scientific article published on 05 January 2015

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

scientific article

Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer

scientific article

Reply to S. Mahesh

scientific article

Stemming resistance to HER-2 targeted therapy

scientific article published on 04 March 2009

Targeted therapies in breast cancer: are heart and vessels also being targeted?

scientific article

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

scientific article

Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer

scientific article published on 08 December 2009

The evolving role of aromatase inhibitors in adjuvant breast cancer therapy

scientific article

Trastuzumab (herceptin) for early-stage breast cancer

scientific article published on April 2007

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

scientific article

Trastuzumab for early breast cancer: current status and future directions.

scientific article published on September 2007

Paulina is supported by:

About Paulina

Help